315 related articles for article (PubMed ID: 31695794)
1. Blood TfR+ exosomes separated by a pH-responsive method deliver chemotherapeutics for tumor therapy.
Yang L; Han D; Zhan Q; Li X; Shan P; Hu Y; Ding H; Wang Y; Zhang L; Zhang Y; Xue S; Zhao J; Hou X; Wang Y; Li P; Yuan X; Qi H
Theranostics; 2019; 9(25):7680-7696. PubMed ID: 31695794
[TBL] [Abstract][Full Text] [Related]
2. Exosomes separated based on the "STOP" criteria for tumor-targeted drug delivery.
Qi H; Yang L; Li X; Zhan Q; Han D; Zhao J; Hou X; Yuan X
J Mater Chem B; 2018 May; 6(18):2758-2768. PubMed ID: 32254228
[TBL] [Abstract][Full Text] [Related]
3. SPION decorated exosome delivery of TNF-α to cancer cell membranes through magnetism.
Zhuang M; Chen X; Du D; Shi J; Deng M; Long Q; Yin X; Wang Y; Rao L
Nanoscale; 2020 Jan; 12(1):173-188. PubMed ID: 31803890
[TBL] [Abstract][Full Text] [Related]
4. Blood Exosomes Endowed with Magnetic and Targeting Properties for Cancer Therapy.
Qi H; Liu C; Long L; Ren Y; Zhang S; Chang X; Qian X; Jia H; Zhao J; Sun J; Hou X; Yuan X; Kang C
ACS Nano; 2016 Mar; 10(3):3323-33. PubMed ID: 26938862
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
6. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors.
Jang SC; Kim OY; Yoon CM; Choi DS; Roh TY; Park J; Nilsson J; Lötvall J; Kim YK; Gho YS
ACS Nano; 2013 Sep; 7(9):7698-710. PubMed ID: 24004438
[TBL] [Abstract][Full Text] [Related]
7. Multifunctional PLGA nanoparticles combining transferrin-targetability and pH-stimuli sensitivity enhanced doxorubicin intracellular delivery and in vitro antineoplastic activity in MDR tumor cells.
Scheeren LE; Nogueira-Librelotto DR; Mathes D; Pillat MM; Macedo LB; Mitjans M; Vinardell MP; Rolim CMB
Toxicol In Vitro; 2021 Sep; 75():105192. PubMed ID: 33984456
[TBL] [Abstract][Full Text] [Related]
8. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
9. Engineering blood exosomes for tumor-targeting efficient gene/chemo combination therapy.
Zhan Q; Yi K; Qi H; Li S; Li X; Wang Q; Wang Y; Liu C; Qiu M; Yuan X; Zhao J; Hou X; Kang C
Theranostics; 2020; 10(17):7889-7905. PubMed ID: 32685027
[No Abstract] [Full Text] [Related]
10. Fattigation-platform nanoparticles using apo-transferrin stearic acid as a core for receptor-oriented cancer targeting.
Amin HH; Meghani NM; Park C; Nguyen VH; Tran TT; Tran PH; Lee BJ
Colloids Surf B Biointerfaces; 2017 Nov; 159():571-579. PubMed ID: 28854413
[TBL] [Abstract][Full Text] [Related]
11. Tailor-made legumain/pH dual-responsive doxorubicin prodrug-embedded nanoparticles for efficient anticancer drug delivery and in situ monitoring of drug release.
Li Y; Niu Y; Zhu J; Gao C; Xu Q; He Z; Chen D; Xu M; Liu Y
Nanoscale; 2020 Jan; 12(4):2673-2685. PubMed ID: 31942900
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Glioma Cells' Proliferation by Doxorubicin-Loaded Exosomes via Microfluidics.
Thakur A; Sidu RK; Zou H; Alam MK; Yang M; Lee Y
Int J Nanomedicine; 2020; 15():8331-8343. PubMed ID: 33149579
[TBL] [Abstract][Full Text] [Related]
13. Stepwise pH-responsive nanoparticles for enhanced cellular uptake and on-demand intracellular release of doxorubicin.
Chen WL; Li F; Tang Y; Yang SD; Li JZ; Yuan ZQ; Liu Y; Zhou XF; Liu C; Zhang XN
Int J Nanomedicine; 2017; 12():4241-4256. PubMed ID: 28652730
[TBL] [Abstract][Full Text] [Related]
14. High drug loading and pH-responsive targeted nanocarriers from alginate-modified SPIONs for anti-tumor chemotherapy.
Peng N; Wu B; Wang L; He W; Ai Z; Zhang X; Wang Y; Fan L; Ye Q
Biomater Sci; 2016 Nov; 4(12):1802-1813. PubMed ID: 27792228
[TBL] [Abstract][Full Text] [Related]
15. A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer.
Li Y; Gao Y; Gong C; Wang Z; Xia Q; Gu F; Hu C; Zhang L; Guo H; Gao S
Nanomedicine; 2018 Oct; 14(7):1973-1985. PubMed ID: 29935333
[TBL] [Abstract][Full Text] [Related]
16. Enhanced tumor delivery and antitumor response of doxorubicin-loaded albumin nanoparticles formulated based on a Schiff base.
Li F; Zheng C; Xin J; Chen F; Ling H; Sun L; Webster TJ; Ming X; Liu J
Int J Nanomedicine; 2016; 11():3875-90. PubMed ID: 27574421
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
18. Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy.
Amreddy N; Muralidharan R; Babu A; Mehta M; Johnson EV; Zhao YD; Munshi A; Ramesh R
Int J Nanomedicine; 2015; 10():6773-88. PubMed ID: 26604751
[TBL] [Abstract][Full Text] [Related]
19. A pH-responsive Pickering Nanoemulsion for specified spatial delivery of Immune Checkpoint Inhibitor and Chemotherapy agent to Tumors.
Jia L; Pang M; Fan M; Tan X; Wang Y; Huang M; Liu Y; Wang Q; Zhu Y; Yang X
Theranostics; 2020; 10(22):9956-9969. PubMed ID: 32929327
[No Abstract] [Full Text] [Related]
20. A novel delivery system of doxorubicin with high load and pH-responsive release from the nanoparticles of poly (α,β-aspartic acid) derivative.
Wang X; Wu G; Lu C; Zhao W; Wang Y; Fan Y; Gao H; Ma J
Eur J Pharm Sci; 2012 Aug; 47(1):256-64. PubMed ID: 22522116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
